MOESM1 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Authors :: Rosenstock, Julio
Perkovic, Vlado
Alexander, John
Cooper, Mark
Marx, Nikolaus
Pencina, Michael
Toto, Robert
Wanner, Christoph
Zinman, Bernard
Baanstra, David
Pfarr, Egon
Mattheus, Michaela
Broedl, Uli
Hans-Juergen Woerle
Jyothis George
Eynatten, Maximilian
McGuire, Darren
Publication Year :: 2018
Publisher :: figshare, 2018.
Abstract: Additional file 1. Full inclusion and exclusion criteria for CARMELINAÂŽ.

Full Text Access

Tools